Evaluation of On-Couch CBCT Image Quality

Varian

Status

Enrolling

Conditions

Pelvic Cancer

Abdominal Cancer

Head and Neck Cancer

Thoracic Cancer

Treatments

Device: HyperSight Imaging

Study type

Interventional

Funder types

Industry

Identifiers

NCT06576908

VAR-2023-07

Details and patient eligibility

About

This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology (HyperSight) in patients receiving radiation treatment for cancer on a C-arm linear accelerator (TrueBeam).

Enrollment

46 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient age is ≥ 18 years old.
Patient has a diagnosis of primary or metastatic cancer, including but not limited to tumors arising from or involving the head/neck, lungs, liver, pancreas, prostate, urinary bladder, rectum, cervix or uterus.
A previous (standard-of-care) decision was made to treat the patient with radiation therapy using a Varian TrueBeam treatment system.
A previous (standard-of-care) decision was made to treat the patient with a radiation dose of at least 20 Gy in at least 5 fractions, one fraction per day on consecutive days, Monday to Friday.
Patient is willing and able to provide informed consent to participate in the study.

Exclusion criteria

Patient is pregnant or has plans for pregnancy during the period of treatment.
Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").